Can an adult on terbinafine 250 mg daily for onychomycosis safely take fluconazole (Diflucan) for another infection?

Can Terbinafine and Fluconazole Be Taken Together?

Proceed with extreme caution—concurrent use of terbinafine and fluconazole is not recommended due to the risk of additive hepatotoxicity and potential drug interactions, though no absolute contraindication exists in the FDA labeling.

Primary Safety Concern: Hepatotoxicity

Both terbinafine and fluconazole carry significant hepatotoxic potential, and combining them substantially increases the risk of liver injury:

• Terbinafine has documented cases of liver failure requiring transplantation or resulting in death 1
• Fluconazole requires liver function monitoring, especially with high-dose or prolonged therapy 2
• Baseline liver function tests are mandatory for both medications before initiation 2, 1

The additive hepatotoxic risk makes concurrent use particularly hazardous, especially since both drugs are metabolized hepatically and can cause transaminase elevations.

Drug Interaction Considerations

The FDA label for terbinafine specifically mentions that terbinafine has an effect on the metabolism of fluconazole 1. While the clinical significance isn't fully detailed, this interaction warrants careful consideration:

• Terbinafine is a CYP2D6 inhibitor 1
• Fluconazole inhibits CYP3A4, CYP2C9, and CYP2C19 3
• The overlapping metabolic pathways create unpredictable drug level alterations

Clinical Context and Alternatives

If a patient on terbinafine 250 mg daily for onychomycosis develops another fungal infection requiring treatment:

Preferred Approach:

1. Assess the urgency of treating the second infection
2. Consider topical alternatives for the new infection if possible
3. If systemic therapy is absolutely necessary, consider:
   • Temporarily discontinuing terbinafine (given its long half-life of 24-156 days in nails, therapeutic levels persist) 3
   • Using a non-azole antifungal if appropriate for the indication
   • Close hepatic monitoring if concurrent use is unavoidable

If Concurrent Use Cannot Be Avoided:

• Obtain baseline and weekly liver function tests for the first month
• Monitor for symptoms of hepatotoxicity: nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools 1
• Discontinue both medications immediately if transaminases exceed 3x upper limit of normal or if symptoms develop
• Use the shortest possible duration of overlapping therapy

Important Caveats

The British Association of Dermatologists guidelines position fluconazole as an alternative when patients cannot tolerate terbinafine or itraconazole 2, suggesting these agents are typically used sequentially, not concurrently. The guideline mentions combination therapy refers to systemic plus topical agents, not dual systemic antifungals 2.

Common pitfall: Assuming that because both drugs are antifungals they can be safely combined. The reality is that their overlapping toxicity profiles and metabolic interactions create substantial risk without clear benefit, as there's no evidence supporting improved efficacy with combination systemic azole-allylamine therapy for any indication.

Bottom line: Unless there is a compelling, life-threatening indication requiring both medications simultaneously with no alternatives available, avoid concurrent use. If unavoidable, implement intensive hepatic monitoring and use the shortest possible duration of overlap.